NYSE:AMRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. More Details


Snowflake Analysis

Very undervalued with limited growth.


Similar Companies

Share Price & News

How has Amneal Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AMRX's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

1.0%

AMRX

2.2%

US Pharmaceuticals

-1.0%

US Market


1 Year Return

-5.3%

AMRX

3.5%

US Pharmaceuticals

19.6%

US Market

Return vs Industry: AMRX underperformed the US Pharmaceuticals industry which returned 3.7% over the past year.

Return vs Market: AMRX underperformed the US Market which returned 19.6% over the past year.


Shareholder returns

AMRXIndustryMarket
7 Day1.0%2.2%-1.0%
30 Day6.4%4.5%2.2%
90 Day-6.2%8.7%11.5%
1 Year-5.3%-5.3%7.0%3.5%22.3%19.6%
3 Yearn/a22.8%13.3%45.3%35.7%
5 Yearn/a52.5%34.4%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Amneal Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amneal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMRX ($4.83) is trading below our estimate of fair value ($9.9)

Significantly Below Fair Value: AMRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMRX is good value based on its PE Ratio (11.4x) compared to the US Pharmaceuticals industry average (24.1x).

PE vs Market: AMRX is good value based on its PE Ratio (11.4x) compared to the US market (21x).


Price to Earnings Growth Ratio

PEG Ratio: AMRX is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: AMRX is good value based on its PB Ratio (2.4x) compared to the US Pharmaceuticals industry average (4.4x).


Next Steps

Future Growth

How is Amneal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

13.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRX's forecast earnings growth (13.3% per year) is above the savings rate (2%).

Earnings vs Market: AMRX's earnings (13.3% per year) are forecast to grow slower than the US market (21.6% per year).

High Growth Earnings: AMRX's earnings are forecast to grow, but not significantly.

Revenue vs Market: AMRX's revenue (2% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: AMRX's revenue (2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMRX's Return on Equity is forecast to be very high in 3 years time (51.3%).


Next Steps

Past Performance

How has Amneal Pharmaceuticals performed over the past 5 years?

-63.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMRX has a large one-off loss of $293.8M impacting its September 30 2020 financial results.

Growing Profit Margin: AMRX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: AMRX's earnings have declined by 63.3% per year over the past 5 years.

Accelerating Growth: AMRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AMRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: AMRX's Return on Equity (3%) is considered low.


Next Steps

Financial Health

How is Amneal Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AMRX's short term assets ($1.5B) exceed its short term liabilities ($667.9M).

Long Term Liabilities: AMRX's short term assets ($1.5B) do not cover its long term liabilities ($3.0B).


Debt to Equity History and Analysis

Debt Level: AMRX's debt to equity ratio (800.2%) is considered high.

Reducing Debt: Insufficient data to determine if AMRX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: AMRX's debt is not well covered by operating cash flow (7.7%).

Interest Coverage: AMRX's interest payments on its debt are not well covered by EBIT (1x coverage).


Balance Sheet


Next Steps

Dividend

What is Amneal Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: AMRX is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Chirag Patel (53 yo)

1.42yrs

Tenure

US$337,967

Compensation

Mr. Chirag K. Patel has been Co-Chief Executive Officer and President of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as Director an...


Leadership Team

NamePositionTenureCompensationOwnership
Chirag Patel
Co-Founder1.42yrsUS$337.97k0.25%
$ 3.6m
Chintu Patel
Co-Founder19yrsUS$339.60k0.24%
$ 3.5m
Andrew Boyer
Executive VP & Chief Commercial Officer of Generics2.92yrsUS$3.11m0.074%
$ 1.1m
Anastasios Konidaris
Executive VP & CFO0.83yrno datano data
Stephen Manzano
Senior VP1yrno datano data
James Luce
Executive Vice President of Sales & Marketingno datano datano data
Nikita Shah
Executive VP and Chief Human Resources Officer & Strategic Planning Officer7yrsUS$1.54m0.12%
$ 1.8m
Sanjiv Patel
Senior Vice President of Operationsno datano datano data
Candis Edwards
Senior Vice President of Regulatory Affairsno datano datano data
Joseph Todisco
Executive VP & Chief Commercial Officer of Specialty2.67yrsno data0.17%
$ 2.5m
Nikunj Patel
Head of Ops & Executive VP of Amneal Pharmaceuticals (India) Pvt Ltdno datano datano data
Sanjay Jain
President of India Operations2yrsno datano data

1.7yrs

Average Tenure

53yo

Average Age

Experienced Management: AMRX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Chirag Patel
Co-Founder1.42yrsUS$337.97k0.25%
$ 3.6m
Chintu Patel
Co-Founder19yrsUS$339.60k0.24%
$ 3.5m
Kanubhai Patel
Chairman & MD of Amneal Pharmaceuticals (India) Pvt Ltdno datano datano data
Paul Meister
Independent Chairman of the Board1.42yrsUS$305.77k0.26%
$ 3.7m
J. Buchi
Independent Director2.67yrsUS$390.26k0.016%
$ 234.1k
Ted Nark
Independent Director2.67yrsUS$379.23k0.042%
$ 613.6k
Shlomo Yanai
Independent Director1.08yrsUS$112.16k0.0051%
$ 73.8k
Mark Schlossberg
Directorno datano datano data
Jeffrey George
Independent Director1.08yrsUS$112.16k0.021%
$ 307.2k
Gautam Patel
Director2.67yrsUS$355.90k8.84%
$ 128.0m
Emily Alva
Director2.67yrsUS$358.84k0.0085%
$ 123.2k
John Kiely
Independent Director1.08yrsUS$112.16k0.012%
$ 171.9k

2.7yrs

Average Tenure

59yo

Average Age

Experienced Board: AMRX's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Amneal Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amneal Pharmaceuticals, Inc.
  • Ticker: AMRX
  • Exchange: NYSE
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.448b
  • Market Cap: US$713.045m
  • Shares outstanding: 299.75m
  • Website: https://www.amneal.com

Number of Employees


Location

  • Amneal Pharmaceuticals, Inc.
  • 400 Crossing Boulevard
  • 3rd Floor
  • Bridgewater
  • New Jersey
  • 8807
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMRXNYSE (New York Stock Exchange)YesClass A Common SharesUSUSDMay 2018
2DTDB (Deutsche Boerse AG)YesClass A Common SharesDEEURMay 2018

Biography

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeut...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 23:42
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.